Latest News on SHC

Financial News Based On Company


Advertisement
Advertisement

Jefferies reiterates Sotera Health stock buy rating at $20 target By Investing.com

https://in.investing.com/news/stock-market-news/jefferies-reiterates-sotera-health-stock-buy-rating-at-20-target-93CH-5712991
Jefferies has reiterated its Buy rating for Sotera Health (NASDAQ: SHC) with a $20.00 price target. The firm's decision follows a presentation by newly appointed CEO Alton Shader, who highlighted the company's critical role in healthcare supply, its strong financial profile with high margins and improving free cash flow, and plans for growth through disciplined capital deployment. InvestingPro analysis suggests the stock is undervalued, trading at a low P/E ratio relative to near-term earnings growth.

Sotera Health at Jefferies Global Healthcare Conference: growth stays steady

https://www.investing.com/news/transcripts/sotera-health-at-jefferies-global-healthcare-conference-growth-stays-steady-93CH-5035811
Sotera Health outlined its business strategy at the Jefferies Global Healthcare Conference, emphasizing consistent long-term growth in its sterilization and testing businesses despite recent short-term demand softness in Europe and parts of medtech. The company highlighted its strong financial profile with a 7% compound annual growth rate in revenue and EBITDA since its 2020 IPO, a 51% EBITDA margin, and robust free cash flow generation. Management reiterated its focus on organic growth within its three existing business units, operational excellence, and disciplined capital allocation, while also pursuing strategic M&A in sterilization services.

SHC: 2027 lower capex and integrated customer growth underpin the outlook amid near-term Sterigenics softness

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4682339:0-shc-2027-lower-capex-and-integrated-customer-growth-underpin-the-outlook-amid-near-term-sterigenics-softness/
Sotera Health Company (SHC), a global sterilization and testing platform, projects 5%–7% annual revenue growth from 2025–2027, focusing on customer integration, capacity expansion, and sterilization M&A. Despite near-term softness in European MedTech, with Q4 2026 Sterigenics growth guided at 6% constant currency, lower capital expenditures in 2027 are expected to boost cash flow. This outlook is based on insights from the Jefferies Global Healthcare Conference.

Sotera Health (SHC) Reaffirms Guidance And Revenue Targets, Is A 23% Discount Warranted?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/sotera-health-shc-reaffirms-guidance-and-revenue-targets-is
Sotera Health (SHC) has reaffirmed its 2026 guidance and revenue targets following solid third-quarter results, leading to choppy share price movements. Despite recent short-term weakness, the stock shows longer-term gains, and Simply Wall St's analyst consensus indicates the company is 23% undervalued with a fair value of $21.44. However, ongoing ethylene oxide litigation and high 2026 capital spending are identified as key pressure points.

Is Sotera Health (SHC) Undervalued Following Its Q3 Beat And Reaffirmed Guidance?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/is-sotera-health-shc-undervalued-following-its-q3-beat-and-r
Sotera Health (SHC) recently reaffirmed its 2026 guidance and reported strong Q3 results, yet its share price has declined. While one valuation narrative suggests the stock is 30% undervalued at $22.72 due to high service margins and improving leverage, its current P/E of 26.4x is above its fair ratio of 21.1x, presenting mixed signals for investors. Key risks include ongoing ethylene oxide litigation and significant 2026 CapEx demands.
Advertisement

Sotera Health (SHC) Stock May Look Stretched After Raised Guidance

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/sotera-health-shc-stock-may-look-stretched-after-raised-guid
Sotera Health's shares have recently slipped despite positive earnings, raising questions about whether its current price of US$15.87 is justified by its profitability. While the company's P/E ratio of 26.1x is below the industry average, it still appears overvalued compared to a tailored fair P/E that considers its specific profile and raised full-year guidance. Investors are now evaluating if this premium is warranted by confidence in future execution and cash generation.

Analysts Are Bullish on These Healthcare Stocks: Sotera Health (SHC), Pfizer (PFE)

https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/8680561/analysts-are-bullish-on-these-healthcare-stocks-sotera-health-shc-pfizer-pfe/
BMO Capital analysts have issued bullish ratings for two healthcare stocks: Sotera Health (SHC) and Pfizer (PFE). Sean Dodge reiterated a Buy rating on Sotera Health with a $22.00 price target, while Evan Seigerman maintained a Buy rating on Pfizer with a $35.00 price target. These recommendations come amidst a generally optimistic sentiment in the Healthcare sector.

Barclays maintains Sotera Health at Overweight, lowers price target to $20 from $22

https://www.tradingview.com/news/tradingview:a0983e435bfc5:0-barclays-maintains-sotera-health-at-overweight-lowers-price-target-to-20-from-22/
Barclays has reiterated its "Overweight" rating for Sotera Health (SHC) but has reduced its price target from $22 to $20, representing a 9.1% decrease. Despite the lower target, this still implies a 24.8% upside from the stock's closing price of $16.03 on November 3. Investors can find more detailed analyst ratings and forecasts for Sotera Health on the Forecasts tab and in the dedicated News Flow section.

Sotera Health’s Free Cash Flow Story Runs Through 2027

https://finimize.com/content/sotera-healths-free-cash-flow-story-runs-through-2027
RBC has given Sotera Health a vote of confidence, predicting a significant jump in the company's free cash flow in 2027. This anticipated increase is due to the winding down of heavy capital expenditures related to ethylene oxide facility upgrades and cobalt-loading capacity expansion. Investors are advised to focus on project timelines and capex guidance rather than quarterly earnings volatility to track this cash flow inflection.

What Sotera Health (SHC) Said on Its Q3 Earnings Call

https://es.tradingview.com/news/marketbeat:06b6fed8f094b:0-what-sotera-health-shc-said-on-its-q3-earnings-call/
Sotera Health (SHC) reported solid third-quarter 2026 results, with revenue up 4.4% to $325 million and adjusted EBITDA increasing 3.9% to $171 million, driven by strong performance in Sterigenics and Nelson Labs. Despite reaffirming its full-year outlook, the company noted softer demand from medical-device customers in Europe late in Q3 and continuing into Q4. Nordion revenue declined due to Cobalt-60 harvest timing, but still exceeded expectations.
Advertisement

Sotera Health Releases Q3 2026 Financial Results

https://news.alphastreet.com/sotera-health-releases-q3-2026-financial-results/
Sotera Health Company (SHC) announced third-quarter results for 2026, exceeding Wall Street expectations with adjusted earnings of $0.29 per share, a 7.4% beat over the $0.27 forecast. The company reported revenues of $324.9 million, a 4.4% increase year-over-year, and a net income of $58.4 million. Management also provided full-year 2026 guidance, projecting adjusted EPS between $0.95 and $1.01, and revenue between $1.23 billion and $1.25 billion.

Sotera Health Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62825040/sotera-health-q3-2026-earnings-call-transcript
Sotera Health reported solid third-quarter 2026 financial results, with revenues increasing 4.4% to $325 million and adjusted EBITDA up 3.9% to $171 million. The company reaffirmed its full-year 2026 outlook for constant currency revenue growth of 5.25% to 6.75% and adjusted EBITDA growth of 5.75% to 7.25%, despite some softness in the European medical device market. Sotera Health continues to focus on organic growth, strategic M&A, and leveraging cross-business unit selling opportunities while expecting a significant decrease in capital expenditures in 2027.

Sotera Health Company Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:725514:0-sotera-health-company-q3-2026-earnings-call-is-live/
Sotera Health Company (SHC) has commenced its Q3 2026 earnings call, where executives will discuss the latest financial results and address questions from Wall Street analysts. Investors following SHC can listen to management's commentary on the numbers, which can significantly influence market sentiment, particularly discussions on future demand, margins, or capital spending.

Sotera Health Company’s (NASDAQ:SHC) Q3 2026 sales top estimates, stock jumps 12.9%

https://stockstory.org/us/stocks/nasdaq/shc/news/earnings/sotera-health-companys-nasdaqshc-q3-2026-sales-top-estimates-stock-jumps-129percent
Sotera Health Company (NASDAQ:SHC) exceeded Wall Street's revenue and adjusted EPS expectations in Q3 2026, with revenue rising 4.4% year-on-year to $324.9 million. Despite a decline in adjusted operating margin, the company reconfirmed its full-year revenue and adjusted EPS guidance, leading to a 12.9% jump in its stock price immediately after the results. Analysts anticipate continued revenue growth over the next 12 months, driven by new products and services.

Sotera Health Reports Q3 2026: Cash Reserves Increase to $412.4 Million

https://kalkinemedia.com/us/news/announcements/sotera-health-reports-q3-2026-cash-reserves-increase-to-4124-million
Sotera Health Company (NASDAQ:SHC) reported its Q3 2026 financial results, showing a significant increase in cash and cash equivalents to $412.4 million as of September 30, 2026, up from $344.6 million at the end of 2025. The company filed its Form 10-Q with the SEC, detailing its financial position, 285.6 million shares outstanding, and highlighting ongoing risks related to ethylene oxide emissions litigation and leverage.
Advertisement

Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results

https://www.manilatimes.net/2026/11/03/tmt-newswire/globenewswire/sotera-health-reports-solid-third-quarter-and-year-to-date-2026-results/2460486
Sotera Health Company (Nasdaq: SHC) reported strong financial results for the third quarter and first nine months of 2026, with net revenues increasing 4.4% and Adjusted EBITDA up 3.9% in Q3. The company reaffirmed its full-year 2026 outlook for constant currency revenue growth of 5.25% - 6.75% and Adjusted EBITDA growth of 5.75% - 7.25%, driven by solid performance in its Sterigenics and Nelson Labs segments. Sotera Health also highlighted continued deleveraging, achieving a Net Leverage Ratio of 2.9x and a credit rating upgrade from Moody's Ratings.

Sotera Health Company’s (NASDAQ:SHC) Q3 2026 sales top estimates, stock jumps 12.9%

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-3-sotera-health-companys-nasdaqshc-q3-2026-sales-top-estimates-stock-jumps-129
Sotera Health Company (NASDAQ: SHC) exceeded Wall Street's revenue expectations for Q3 2026, with revenue increasing by 4.4% year-on-year to $324.9 million, and non-GAAP profit per share beating estimates by 8%. Despite a mediocre 6.3% compounded annual revenue growth over the last five years, the company's Q3 performance, including an adjusted EPS of $0.29, led to its shares jumping 12.9% immediately after the results. The company reconfirmed its full-year revenue and adjusted EPS guidance, aligning with analysts' consensus.

Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results

https://www.globenewswire.com/news-release/2026/11/03/3394046/0/en/sotera-health-reports-solid-third-quarter-and-year-to-date-2026-results.html
Sotera Health (Nasdaq: SHC) announced strong third-quarter and year-to-date 2026 financial results, including a 4.4% increase in Q3 net revenues and a 3.9% rise in Adjusted EBITDA. The company reaffirmed its full-year 2026 outlook for net revenue growth of 5.25% - 6.75% and Adjusted EBITDA growth of 5.75% - 7.25% on a constant currency basis. Key drivers included robust performance from its Sterigenics and Nelson Labs segments, alongside continued deleveraging and a credit rating upgrade from Moody's Ratings.

What to expect from Sotera Health Company’s (SHC) Q3 earnings

https://stockstory.org/us/stocks/nasdaq/shc/news/earnings/what-to-expect-from-sotera-health-companys-shc-q3-earnings-2
Sotera Health (NASDAQ:SHC) is set to report its Q3 earnings, with analysts expecting a 2.7% year-on-year revenue growth. The company has a history of exceeding Wall Street's expectations and delivered strong results last quarter, beating revenue and EPS estimates. Peer performance in the research tools & consumables segment has been mixed, with Avantor and Thermo Fisher reporting revenue growth but seeing their share prices decline post-results.

Vanguard reports a passive stake above 5% in Sotera Health (SHC).

https://www.stocktitan.net/sec-filings/SHC/schedule-13g-sotera-health-co-passive-investment-disclosure-5-151b00d0123b.html
Vanguard Capital Management reported a beneficial ownership of 14,625,165 common shares, or 5.12% of Sotera Health Co (SHC), as of September 30, 2026, through a SCHEDULE 13G filing. This passive investment grants Vanguard sole voting power over 2,235,378 shares and sole dispositive power over all 14,625,165 shares. The filing indicates that Vanguard and its affiliates have the right to receive or direct dividends and sale proceeds from these securities.
Advertisement

Sotera Health Company Estimates – NASDAQ:SHC

https://www.tradingview.com/symbols/NASDAQ-SHC/financials-estimates/
This page provides financial actuals and analyst estimates for Sotera Health Company (NASDAQ: SHC), covering its income statement, balance sheet, cash flow statement, and valuation metrics. Users can explore reported financial data, compare actual results with average, high, and low estimates, and visualize trends over time. It is important to note that the information presented is not investment advice.

Piper Sandler Maintains Sotera Health Company(SHC.US) With Buy Rating, Maintains Target Price $25

https://www.moomoo.com/news/post/1001586120/piper-sandler-maintains-sotera-health-company-shcus-with-buy-rating
Piper Sandler has reiterated its Buy rating for Sotera Health Company (SHC.US), keeping its target price at $25. This indicates continued confidence in the company's performance and future prospects from the analyst firm.

Sotera Health Announces Third-Quarter 2026 Earnings Release Date

https://www.streetinsider.com/Press+Releases/Sotera+Health+Announces+Third-Quarter+2026+Earnings+Release+Date/27212784.html
Sotera Health Company announced it will release its third-quarter financial results for the period ended September 30, 2026, before market open on Tuesday, November 3, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Time to discuss the results. A live webcast and materials will be available via the Investor Relations section of the company's website.

Sotera Health Announces Third-Quarter 2026 Earnings Release Date

https://www.streetinsider.com/dr/news.php?id=27212784
Sotera Health Company announced that it will release its third-quarter 2026 financial results before the market opens on Tuesday, November 3, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Time to discuss the operating and financial results, with a live webcast available on the Company's Investor Relations website.

Sotera Health Announces Third-Quarter 2026 Earnings Release Date

https://www.globenewswire.com/news-release/2026/10/21/3385379/0/en/sotera-health-announces-third-quarter-2026-earnings-release-date.html
Sotera Health Company announced it will release its financial results for the third quarter ended September 30, 2026, before market open on Tuesday, November 3, 2026. Management will host a conference call at 9:00 a.m. Eastern Time to discuss the results, with a live webcast available through the company's Investor Relations website.
Advertisement

JPMorgan cuts target for Sotera Health stock from USD 18 to USD 17

https://www.ad-hoc-news.de/boerse/news/nebenwerte/jpmorgan-cuts-target-for-sotera-health-stock-from-usd-18-to-usd-17/70376329
JPMorgan has lowered its price target for Sotera Health (SHC) stock from USD 18.00 to USD 17.00 and downgraded its rating from Neutral to Underweight. This comes despite Sotera Health reporting a 9.20% increase in second-quarter 2026 revenue to USD 321.38 million. The bank cited uncertainty regarding future volume growth and the medical device end market as reasons for the downgrade, ahead of the company's third-quarter 2026 results announcement on November 3, 2026.

2 Profitable Stocks to Keep an Eye On and 1 We Question

https://stockstory.org/us/stocks/nasdaq/shc/news/buy-or-sell/2-profitable-stocks-to-keep-an-eye-on-and-1-we-question
This article analyzes three companies: Sotera Health (SHC), Insulet (PODD), and WEX (WEX), assessing their profitability and future prospects. It recommends selling SHC due to underperforming core business and weak free cash flow, while suggesting PODD and WEX as stocks to watch, highlighting their strong growth, expanding margins, and effective management. The analysis is based on financial metrics like GAAP operating margin, constant currency growth, and free cash flow.

2 Profitable Stocks to Keep an Eye On and 1 We Question

https://www.financialcontent.com/article/stockstory-2026-10-19-2-profitable-stocks-to-keep-an-eye-on-and-1-we-question
This article analyzes three profitable companies, recommending two as potential buys and one as a stock to consider selling. It highlights Insulet (PODD) and WEX (WEX) for their strong financial performance and growth prospects, while advising caution on Sotera Health (SHC) due to underperforming core business and weak free cash flow. The analysis considers various financial metrics and business models to assess long-term viability.

RBC sets USD 24.00 target for Sotera Health stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rbc-sets-usd-24-00-target-for-sotera-health-stock/70348542
RBC Capital has set a USD 24.00 price target for Sotera Health (SHC) stock, maintaining a Buy rating. This target is 34.15 percent above the Nasdaq price of USD 17.89 as of October 16, 2026. Sotera Health's stock has gained 1.42 percent year-to-date and its next earnings date is estimated to be November 3, 2026.

JPMorgan cuts target to USD 17.00 for Sotera Health stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/jpmorgan-cuts-target-to-usd-17-00-for-sotera-health-stock/70332945
JPMorgan has downgraded Sotera Health (SHC) from Neutral to Underweight and reduced its price target from USD 18.00 to USD 17.00. The stock was trading at EUR 16.20 on October 15, 2026, up 1.89 percent versus the Tradegate close. Sotera Health reported strong Q2 2026 results with revenue up 9.20 percent year over year, and its next quarterly report is due on November 3, 2026.
Advertisement

Sachem Head Capital Management LP Exits Sotera Health Co (SHC) -- Shares Look 7% Overvalued on GF Value

https://www.gurufocus.com/news/9124855/sachem-head-capital-management-lp-exits-sotera-health-co-shc-shares-look-7-overvalued-on-gf-value
Sachem Head Capital Management LP has completely divested its 15,560,000 shares in Sotera Health Co (SHC), a move that impacted its portfolio by -5.73%. This exit suggests the firm views SHC as fully valued, as the stock trades slightly above its GF Value estimate. Sotera Health, a provider of sterilization and testing services, currently has a "Fairly Valued" GF Valuation and a GF-Score of 76/100, indicating average future performance potential.

JPMorgan Downgrades Sotera Health to Underweight From Neutral, Price Target is $17

https://finance.yahoo.com/markets/stocks/articles/jpmorgan-downgrades-sotera-health-underweight-100300837.html
JPMorgan has downgraded Sotera Health (SHC) from Neutral to Underweight, setting a price target of $17. This change in rating comes despite Sotera Health having an average analyst rating of buy and a mean price target of $22.72. The article, sourced from MT Newswires, notes that premium access is required for full details.

Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage

https://seekingalpha.com/news/4653058-bruker-sotera-downgraded-jp-morgan
J.P. Morgan downgraded Bruker Corporation (BRKR) and Sotera Health (SHC) to Neutral as part of a review of its life science tools & diagnostics coverage. This decision comes ahead of the sector's upcoming earnings season.

J.P. Morgan Downgrades Sotera Health Company(SHC.US) to Sell Rating, Raises Target Price to $17

https://www.moomoo.com/news/post/1001157873/jp-morgan-downgrades-sotera-health-company-shcus-to-sell-rating
J.P. Morgan has downgraded Sotera Health Company (SHC.US) from a Neutral to a Sell rating. Despite the downgrade, the firm increased its price target for SHC to $17. This indicates a more cautious outlook on the company's stock performance while adjusting expectations for its valuation.

How Investors May Respond To Sotera Health (SHC) Raised 2026 Outlook

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/how-investors-may-respond-to-sotera-health-shc-raised-2026-o
Sotera Health (SHC) recently reported strong Q2 2026 revenue growth and raised its full-year guidance for both revenue and adjusted EBITDA, coinciding with a new CEO focusing on customer-centric execution. The company is making significant investments in EO controls and cobalt 60 capacity, and new DCF analysis suggests its intrinsic value is above its current share price. Investors are now evaluating whether these investments and positive quarterly results can lead to sustained cash generation, despite ongoing risks related to EO regulation, litigation, and leverage.
Advertisement

An investment adviser and three related parties report no shares in Sotera Health (SHC).

https://www.stocktitan.net/sec-filings/SHC/schedule-13g-a-sotera-health-co-amended-passive-investment-disclosure-d365e4ebc986.html
Sachem Head Capital Management LP, along with Uncas GP LLC, Sachem Head GP LLC, and Scott D. Ferguson, have filed an amended Schedule 13G/A for Sotera Health Co (SHC), reporting zero beneficial ownership of common shares. This filing indicates that these four reporting persons hold no sole or shared voting and dispositive power over SHC stock. The reported ownership percentage for each entity is 0.0%.

Transcript: Sotera Health Q2 2026 Earnings Conference Call

https://www.benzinga.com/news/26/10/62265813/transcript-sotera-health-q2-2026-earnings-conference-call
Sotera Health reported strong Q2 2026 earnings with 8% constant currency revenue growth and 8.7% constant currency adjusted EBITDA growth, leading to a raised full-year outlook. The company's new CEO, Alton Shader, outlined priorities including talent assessment, customer partnerships, and leveraging "One Sotera" offerings, while CFO John Lyons detailed segment-specific performance and financial improvements. Noteworthy developments include the retirement of Nelson Labs' president, leadership transition to Riaz Bandali, and progress on X-ray capacity expansion.

Sotera Health Company (SHC) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_6056_QuantitativeReport_1790726400000
This article provides a brief overview of Sotera Health Company (SHC), detailing its services in sterilization, analytical lab testing, and advisory services for medical, pharmaceutical, and food products. It highlights Argus's perspective on SHC, including its current price and a link to download the full report. The company aims to ensure product safety for healthcare practitioners, patients, and consumers.

Sotera Health (SHC) Pullback Raises The Question As Undervaluation Claims Persist

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/sotera-health-shc-pullback-raises-the-question-as-undervalua/amp
Sotera Health (SHC) has experienced a recent stock pullback, declining about 5% over the past month, which has reignited discussions about its valuation. Despite short-term softness, the company has shown resilient longer-term performance with a 1-year total shareholder return of 11.88% and a 3-year return of 32.49%. The article explores whether the current dip presents an undervaluation opportunity, with a widely followed fair value estimate suggesting it is 21% undervalued, or if valuation concerns now take precedence.

Sotera Health (SHC) Pullback Raises The Question As Undervaluation Claims Persist

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/sotera-health-shc-pullback-raises-the-question-as-undervalua
Sotera Health (SHC) has experienced a recent stock pullback, declining about 5% over the past month, which brings its undervaluation claims into focus. The company is priced at $17.90 against a fair value estimate of $22.72, suggesting a valuation gap based on high service margins and improving leverage. However, P/E multiples tell a different story, with SHC trading at 31.2x compared to a fair ratio of 21.9x, prompting questions about potential mispricing versus a margin of safety.
Advertisement

Sotera Health stock carries Barclays Buy rating with USD 22 target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/sotera-health-stock-carries-barclays-buy-rating-with-usd-22-target/70260168
Barclays has maintained a Buy rating on Sotera Health (SHC) with a USD 22 price target, reflecting continued confidence after the company reported strong Q2 revenue growth of 9.2% to USD 321.38 million. The stock closed at USD 18.13 on October 7, 2026, on Nasdaq, and analysts have an average target of USD 21.50, indicating potential upside. Sotera Health is scheduled to report its Q3 2026 results on November 3, 2026, which will be a key event to assess the company's sustained performance.

Barclays Maintains Sotera Health Company(SHC.US) With Buy Rating, Maintains Target Price $22

https://www.moomoo.com/news/post/1000681156/barclays-maintains-sotera-health-company-shcus-with-buy-rating-maintains
Barclays has reiterated its Buy rating for Sotera Health Company (SHC.US), maintaining a target price of $22. This indicates Barclays' continued confidence in the company's financial prospects and stock performance.

Sotera Health stock gains 1.89 percent as Q2 growth supports outlook

https://www.ad-hoc-news.de/boerse/news/corporate-news/sotera-health-stock-gains-1-89-percent-as-q2-growth-supports-outlook/70235753
Sotera Health stock (SHC) gained 1.89% on October 5, 2026, following strong second-quarter results. The company reported a 9.2% year-over-year revenue increase to $321.38 million and adjusted EPS of $0.26, exceeding analyst expectations. Analysts maintain a "Moderate Buy" consensus with a 12-month target price of $21.50, indicating potential upside.

Analysts set USD 21.50 target for Sotera Health stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/analysts-set-usd-21-50-target-for-sotera-health-stock/70212973
Analysts have set an average 12-month target of USD 21.50 for Sotera Health (SHC) stock, significantly above its current Nasdaq trading price. This comes as the company reported a 9.20% year-over-year revenue increase in Q2 2026 and improved operating profit. Sotera Health is also planning significant capital spending for compliance upgrades, Cobalt-60 development, and new sterilization capacity.

Sotera Health stock reports 9.2 percent revenue growth in Q2

https://www.ad-hoc-news.de/boerse/news/nebenwerte/sotera-health-stock-reports-9-2-percent-revenue-growth-in-q2/70181331
Sotera Health (SHC) reported significant Q2 2026 results, with revenue growing 9.2% year-over-year to $321.375 million and net income soaring to $54 million from $8 million in the prior year. The company's adjusted EPS of $0.26 surpassed analyst expectations, and its stock was trading at $18.45 on Nasdaq, near its 52-week high. Analysts, like Piper Sandler, have reiterated an "Overweight" rating with a $25.00 price target, highlighting the company's strong performance in sterilization, laboratory testing, and advisory services.
Advertisement

Sotera Health (SHC) Looks Cheaper As Short Term Momentum Cools

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/sotera-health-shc-looks-cheaper-as-short-term-momentum-cools
Sotera Health (SHC) has seen its short-term momentum cool with a 6.25% share price drop over the past month, yet it still shows positive returns over 90 days and the past year. Despite the recent dip, analysts and intrinsic value estimates suggest the stock is undervalued, with a consensus target of $22.72 against its current trading price of $18.29. Investors are advised to consider underlying numbers and potential risks like ethylene oxide regulations.

Sotera Health Company (SHC) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/SHC/
This article provides a comprehensive overview of Sotera Health Company (SHC), including its current stock price, historical performance, key financial metrics, and analyst ratings. It details the company's business segments: Sterigenics, Nordion, and Nelson Labs, which offer sterilization, lab testing, and advisory services. The report also highlights recent financial performance, earnings trends, and valuation measures.

Sotera Health Company Revenue Breakdown – LS:A2QHA5

https://www.tradingview.com/symbols/LS-A2QHA5/financials-segments/
Sotera Health Company (LS:A2QHA5) generated €990.73 million in revenue last year. Its top-performing segment, Sterigenics, contributed €643.49 million, while the United States was the largest regional contributor with €536.00 million. This data provides a breakdown of the company's revenue by segment and geography.

Sotera Health: Pricing Power And Recurring Revenues Are Growth Drivers (NASDAQ:SHC)

https://seekingalpha.com/article/4947933-sotera-health-pricing-power-and-recurring-revenues-are-growth-drivers
Sotera Health Company (SHC) is rated as a Buy due to its strong position in medical equipment sterilization, characterized by a vertically integrated model, high customer switching costs, and robust pricing power. The company exceeded Q2 2026 expectations and raised full-year guidance, trading at a discount to peers despite superior margins. While litigation risk from ethylene oxide lawsuits exists, improving leverage and strong free cash flow support the investment case.

Will Earnings Beat Change Sotera Health (SHC) Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/will-earnings-beat-change-sotera-health-shc-narrative
Sotera Health (SHC) recently reported strong Q2 2026 results, raising its full-year outlook due to gains in pricing, volume mix, and efficiency. Management is now exploring M&A, specifically for Sterigenics and other sterilization services, to boost its core earnings engine while navigating ongoing ethylene oxide regulatory and litigation challenges. The article discusses how this stronger guidance and M&A focus influence the existing investment narrative, which relies on volume growth and cash generation.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement